Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 13/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427803 | 1.00 | GRM4 (0.41) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL28902794 | 1.00 | GRM4 (0.41) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL21427882 | 0.88 | SLC10A1 (0.38) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL22906211 | 0.88 | SLC10A1 (0.38) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL20467193 | 0.86 | SLC10A1 (0.42) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL17838291 | 0.86 | SLC10A1 (0.42) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL17838294 | 0.85 | SLC10A1 (0.44) | GRM4SLC10A1ARALDH1A1L3MBTL1 | |
| SCHEMBL17838260 | 0.85 | SLC10A1 (0.44) | GRM4SLC10A1ARALDH1A1L3MBTL1 | |
| SCHEMBL17838303 | 0.85 | GRM4 (0.40) | GRM4SLC10A1NPC1POLBMAPT | |
| SCHEMBL21427892 | 0.85 | GRM4 (0.44) | GRM4SLC10A1NPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-115974753-A | N-containing heterocyclic five-membered ring compound and application | 正大天晴药业集团股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115974754-A | N-containing heterocyclic five-membered ring compound and application | 正大天晴药业集团股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11597716-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597716-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885SLC10A1 35/4885NPC1 95/4885 |
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885SLC10A1 35/4885NPC1 95/4885 |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885SLC10A1 35/4885NPC1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.